Stanford scientists have discovered that cross-linking antigens can overcome sub-type bias in response to multi-strain vaccines and induce patients to have a complete, broad immune response to all included antigens.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford researchers in the Mark Davis Lab have developed a human cell culture system to grow 3D immune organoids within hydrogel structures using limited cellular input that can be adapted to large screening assays for flexible downstream immunological readouts.
Stanford researchers have developed saponin lipid-based nanoparticles in which both toll-like receptor agonists (TLRas) and other potent molecular adjuvants can be encapsulated to improve vaccine potency, increase antibody titers, and induce more robust neutralizing antibody r
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.